Last edition
News about "WuXi"
Aadi Bioscience Signs Licensing Deal with WUXI and HANGZHOU DAC for Novel ADC Portfolio
Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging HANGZHOU DAC's CPT113 linker payload technology targeting each of Protein Tyrosine Kinase 7 (PTK7), Mucin-16 (MUC16) and Seizure Related 6 Homolog (SEZ6).
WUXI | 21/12/2024 | By Aishwarya | 165
WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility
New facility expands integrated drug product R&D and manufacturing services to global customers
WuXi | 27/09/2022 | By Sudeep Soparkar | 363
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy